TB pure : pulmonary rehabilitation to reduce post-tuberculosis morbidity
Active Project Grant Awarded Last action
- Award ID
- R01AI169588
- Recipient
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,288,671
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 63% complete
- Place of performance
- Baltimore, MD 21205, USA
Award details come from USAspending.gov.
Description
- Abstract
- The overarching goal of the pulmonary rehabilitation to reduce post-tuberculosis morbidity (TB pure) project is to measure the effectiveness, feasibility, and cost-effectiveness of a pulmonary rehabilitation (PR) program to prevent post-tuberculosis (TB) respiratory morbidity in india. TB is associated with lung impairment which can persist despite successful completion of TB treatment. There are an estimated 155 million TB survivors globally, yet there are no routinely implemented interventions for addressing post-TB respiratory morbidity. PR is a key component of the management plan for chronic lung diseases and is an effective intervention to improve patient- centered outcomes. However, the clinical benefit of PR, administered during TB treatment, in preventing post- TB respiratory morbidity has not been investigated. Furthermore, despite the long natural history of TB disease and its disproportionate impact in resource limited settings, the feasibility of a home-based PR program for TB patients is unclear. Therefore, the aims of TB pure are: a) to measure the comparative-effectiveness of two home-based PR programs, administered during TB treatment, for preventing post-TB respiratory morbidity; B) to describe the intersection between clinic-level service organization, coach intervention delivery fidelity, and client behavioral action for these two PR programs; C) to compare the costs, cost-effectiveness, and budget impact of the two different PR strategies implemented as a routine program. To achieve these aims, 690 adult drug- sensitive pulmonary TB patients with functional impairment at TB treatment initiation will be enrolled at three geographically and epidemiologically diverse study sites in india. Participants will be randomized in 1:1:1 ratio into one of the following three study arms: a) 2 months of home-based PR during TB treatment (short PR arm); B) 2 months of home-based PR during TB treatment followed by 4 additional months of home-based PR for participants with persistent functional impairment despite 2 months of PR (extended PR arm); C) standard TB treatment without specific PR (standard-of-care arm). The primary outcome will be the 6-minute walk test distance compared between short and extended PR arms, and the standard-of-care arm at 12 months after randomization. We will assess the PR interventions' acceptability to inform adoption of the PR strategies in a programmatic setting by using the theoretical framework for acceptability. Furthermore, we will empirically assess societal costs of the two PR programs at the patient-level, factoring the resource-use in the process of development of programmatic infrastructure, implementation, service delivery, and patient costs. Cost- effectiveness of the two programs will be assessed based on health-related quality of life (HRQOL) outcomes assessment. Our study, if significant, will generate the strongest evidence to date to support routine implementation of a systematic PR program to reduce post-TB respiratory morbidity. Our multidisciplinary team with distinct, yet complementary, expertise and a strong track record of conducting NIH funded TB research in india will ensure the successful execution of the TB pure project.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $446,971 | |
| Amendment | $94,312 | |
| Amendment | $47,029 | |
| Amendment | $430,078 | |
| Amendment | $587,913 | |
| Original award | $682,368 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Symbiosis International - Deemed University | $94,312 | |
| Subrecipient not on record | $47,029 | |
| Trustees Of Boston University | $274,471 | |
| The University Of British Columbia | $42,298 | |
| Subrecipient not on record | $90,742 | |
| Symbiosis International - Deemed University | $101,928 |
Quick answers
Who received award R01AI169588?
R01AI169588 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2023.
How much is award R01AI169588 worth?
$2,288,671 has been obligated on R01AI169588.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award